Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Loyalist who wrote (12992)	10/8/2003 12:42:16 AM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

Probably written August 2002: 2002 Annual Report In January 2001, Dimethaid International entered into an exclusive distribution agreement with Provalis Healthcare Limited for PENNSAID in the UK. As commitments were not met, this agreement was terminated on June 14, 2002. To maintain continuous product supply to patients in the UK, interim distribution arrangements have been made and discussions with new distributors are expected to be completed within the calendar year. Page 24 After PENNSAID approval by the UK Medicines Control Agency, Dimethaid International entered into an exclusive distribution agreement with Provalis Healthcare Ltd., a division of Provalis Plc. Provalis was responsible for all costs associated with marketing, distributing and selling PENNSAID in the UK. Dimethaid International received a fee for these rights and was entitled to a significant share of sales revenue. Following year-end, the agreement had to be terminated after Provalis encountered difficulties meeting contractual obligations. Dimethaid looks forward to signing a new UK marketing partner during the first half of fiscal 2003. Page 20 2003 Annual Report – Page 13 In December 2002, Provalis Healthcare Ltd. Initiated arbitration proceedings, challenging Dimethaid International’s right to terminate an exclusive agreement for PENNSAID in the UK. The Company believes this challenge is without merit and has filed a defense and counterclaim in these proceedings, which are expected to be completed in the next fiscal year. To maintain continuous product supply to UK patients, the Company has made interim distribution arrangements and expects to complete final sales and marketing arrangements for PENNSAID within the calendar year.